An Irreversible Opioid Antagonist Modified Several THC Responses in a Historical Rat Study

A 1981 rat experiment reported that chlornaltrexamine reduced several THC-related effects, including antinociception and hypothermia. The finding suggested opioid-system involvement without establishing that THC is pharmacologically equivalent to an opioid.

The intervention was a research antagonist

Chlornaltrexamine, also called beta-CNA, was described as a long-acting irreversible opioid antagonist. The supplied abstract reports effects on THC responses in rats. It does not describe a clinical intervention or establish applicability to ordinary naloxone administration.

Acute effects and adaptation were both reported

The antagonist inhibited THC-related analgesia and hypothermia, as well as the reported hypothermic tolerance and physical-dependence outcomes. Those are separate comparisons. Modifying an acute response and modifying adaptation to repeated exposure need not involve exactly the same steps.

The mechanistic claim remained broad

The authors suggested common features between cannabinoid and opioid actions and possible opioid-related mechanisms. That interpretation is narrower than proving direct THC binding to an opioid receptor or showing that one pathway explains every cannabinoid effect. The brief abstract supplies no basis for additional unreported doses, sample sizes or endpoints.

The study is useful as historical interaction evidence and a starting point for mechanistic questions. It does not establish a human treatment for cannabis intoxication or dependence. Receptor-system interaction should be described in terms of the tested intervention and outcomes rather than chemical or clinical equivalence.

Related: interpreting cannabis tolerance claims.

Research cited

Tulunay FC; Ayhan IH; Portoghese PS; Takemori AE. Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats. European journal of pharmacology (1981). doi:10.1016/0014-2999(81)90217-x. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A 2026 Cannabis Review Explains Why Potency, Placebo Response and Sedation Need Separate Measures

A 2026 narrative review argues that product potency is not the same as delivered THC dose and that placebo responses remain important among experienced users. Its laboratory framework also distinguishes reduced drug reinforcement from nonspecific sedation. Users can change how they inhale The review notes that participants alter inhalation patterns…

Spread the love

Read Article: A 2026 Cannabis Review Explains Why Potency, Placebo Response and Sedation Need Separate Measures

THC Antinociception Persisted Without the Same Dynorphin Signal in Tolerant Rats

A 1999 rat study found that tolerance weakened THC-related modulation of spinal dynorphin, while antinociception could still occur without the same elevated dynorphin measure. The role of a downstream signal changed with dose and adaptive state. The experiment examined spinal responses The work followed earlier findings linking acute intrathecal THC…

Spread the love

Read Article: THC Antinociception Persisted Without the Same Dynorphin Signal in Tolerant Rats

A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

A 2002 mouse experiment reported fewer antagonist-precipitated withdrawal signs with a Passiflora-derived benzoflavone fraction. The finding concerns a defined experimental preparation and animal model, not a demonstrated treatment for cannabis-use disorder in people. Concurrent and acute interventions were tested Mice received repeated oral THC with or without the fraction. A…

Spread the love

Read Article: A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us